Pharmacogenomics: Unlocking the human genome for better drug therapy

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 101-121

  McLeod, H L ^a   Evans, W E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug response; Metabolism; Polymorphism; SNP

Indexed keywords

AZATHIOPRINE; CAPTOPRIL; CISAPRIDE; CLARITHROMYCIN; DISOPYRAMIDE; ENALAPRIL; LISINOPRIL; MEFLOQUINE; MERCAPTOPURINE; QUINIDINE; SALBUTAMOL; TACRINE; TERFENADINE; TIOGUANINE; WARFARIN; ZILEUTON;

ALZHEIMER DISEASE; ANTICOAGULATION; DRUG DISPOSITION; DRUG MECHANISM; DRUG TARGETING; FORCED EXPIRATORY VOLUME; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENETIC HETEROGENEITY; HUMAN; LONG QT SYNDROME; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG THERAPY; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0035033019     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.101     Document Type: Review

References (78)

1. Pharmacogenomics: Translating functional genomics into rational therapeutics
2. DNA arrays for analysis of gene expression
3. EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia
4. Fluorescence polarization in homogeneous nucleic acid analysis
5. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR
6. Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry
7. Genotyping by mass spectrometry takes flight
8. Multiplexed single nucleotide polymorphism genotyping by oligonucleotide ligation and flow cytometry
9. Detection of single-nucleotide polymorphisms with the WAVE(TM) DNA fragment analysis system
10. From gels to chips: "Minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms
11. A general approach to single-nucleotide polymorphism discovery
12. Pharmacogenetics of cancer therapy: Getting personal
13. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
14. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
15. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
16. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
17. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
18. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
19. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans
20. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity
21. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
22. Thiopurine methyltransferase alleles in British and Ghanaian populations
23. Polymorphism of the thiopurine S-methyltransferase gene in African Americans
24. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
25. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia
26. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism
27. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
28. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
29. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese
30. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
31. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
32. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism
33. High incidence of secondary brain tumours after radiotherapy and antimetabolites
34. beta(2)-adrenergic receptor pharmacogenetics
35. Impact of genetic polymorphisms of the beta(2)-adrenergic receptor on albuterol bronchodilator pharmacodynamics
36. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
37. Human beta-2-adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function
38. Beta 2-adrenoceptor gene polymorphism, body weight, and physical activity
39. Pharmacogenetics of relevant targets in asthma
40. Complex promoter and coding region beta(2)-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
41. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
42. Single nucleotide polymorphism libraries: Why and how are we building them?
43. The essence of SNPs
44. Identification of 167 polymorphism is 88 genes from candidate neurodegeneration pathways
45. Pharmacogetetic predictions of clozapine response
46. Comparative genomic hybridization and chromosomal instability in solid tumors
47. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors
48. Thymidylate synthase inhibitors in cancer therapy: Direct and indirector inhibitors
49. Genomic imbalances associated with acquired resistance to platinum analogues
50. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays
51. Genome-wide analysis of DNA copy-number changes using cDNA microarrays
52. Systematic variation in gene expression patterns in human cancer cell lines
53. Distinct types of diffuse large B-cells lymphoma identified by gene expression profiling
54. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
55. The transcriptional program in the response of human fibroblasts to serum
56. A gene expression database for the molecular pharmacology of cancer
57. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment
58. Clinical trials in the genomic era: Effects of protective genotypes on sample size and duration of trial
59. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
60. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
61. Ethnic differences in drug disposition and response
62. Ethnic differences in catechol O-methyltransferase pharmacogenetics: Frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or SouthWest Asian individuals
63. Methylation pharmacogenetics: Catechol O-methyl-transferase, thiopurine methyltransferase, and histamine N-methyltransferase
64. Association between genetic polymorphisms of the beta2-adrenoceptor and\par response to albuterol in children with and without a history of wheezing
65. Tolerance to beta-agonists during acute brochoconstriction
66. Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adraenoceptors in asthmatic patients
67. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients
68. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalarpril in patients with proteinuric renal disease
69. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension
70. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure
71. Relationship between the angio tensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies
72. Renal hemodynamic changes induced by captopril and\par angiotensin-converting enzyme gene polymorphism
73. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
74. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
75. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management part III
76. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome
77. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
78. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications